explore -WSS

explore

author：knowledge 2025-09-28 01:35:24 - browse：48598

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Acelyrin, a rare IPO success, stumbles in its first big test

Wikipedia

WSS

Private equity could exacerbate cardiology's overuse problem, experts fear

Telehealth for opioid use disorder is lifesaving

New Covid vaccine is recommended for everyone 6 months or older

Takeaways from AdvaMed, the largest medical devices conference

Researchers CRISPR chickens in bid to protect them from bird flu

Bernie Sanders bashes nonprofit hospitals over their tax breaks

entertainment

explore

entertainment

Bright Health sells Medicare Advantage business to Molina

FDA approves updated Covid vaccines

Affirmative action in medical school literally saved lives

Humana CEO Bruce Broussard to step down in 2024

Virginia high school admissions case could be legal follow

Acelyrin, a rare IPO success, stumbles in its first big test

Hollywood unions extend contract negotiations for actors

European regulators consider appeal over Amylyx ALS drug

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Generate Biomedicines machine learning biotech raises $273M

hotspot

Regeneron agrees to White House price limits on anti

Food makers to regulators: Ultra

Acelyrin, a rare IPO success, stumbles in its first big test

Food makers to regulators: Ultra

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Food makers tried to stack nutrition panel with preferred experts

knowledge

focus

Wikipedia

leisure time